metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)
versus regorafenib
	atezolizumab alone
	IMblaze-370 (A ; all population), 2019 Lancet Oncol. 2019; 20:849-861 NCT02788279	RCT	mCRC - 2nd line (L2)	atezolizumab monotherapy	regorafenib	patients with unresectable locally advanced or metastatic colorectal cancer and disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.	90 / 90	some concern	inconclusive	inconclusive 0 % increase in deaths (OS) (PE)
	atezolizumab plus cometinib
	IMblaze-370 (AC ; all population), 2019 Lancet Oncol. 2019; 20:849-861 NCT02788279	RCT	mCRC - 2nd line (L2)	atezolizumab plus cometinib	regorafenib	patients with unresectable locally advanced or metastatic colorectal cancer with disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled.	183 / 90	some concern	inconclusive	inconclusive 0 % increase in deaths (OS) (PE)